BE

Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program

Monday, June 1, 2020 - 6:00am

These data were presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program from May 29-31, 2020.

Key Points: 
  • These data were presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program from May 29-31, 2020.
  • In addition, the data demonstrated the breadth and depth of the shRNA platform, including the concurrent knockdown of up to four genes.
  • We believe combining the knockdown potential of the platform with additional construct enhancements provides tremendous therapeutic optionality to our non-gene edited CYAD-200 series of CAR-T candidates.
  • Celyad will host a conference call to discuss the update from ASCO on Monday, June 1, 2020 at 2 p.m. CEST / 8 a.m. EDT.

iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors

Monday, June 1, 2020 - 6:00am

iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors

Key Points: 
  • iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors
    Cambridge, MA and Gosselies, Belgium June 1, 2020 iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today the appointment ofAnn D. Rhoadsto its Board of Directors.
  • "I am delighted to welcome Ann to our Board of Directors at a transformational point in the companys history.
  • "Ann is a proven leader and brings ideal expertise to our Board.
  • I am thrilled to welcome her to the Board and to draw from her expertise, added Michel Detheux, PhD, President and Chief Executive Officer of iTeos Therapeutics.

MDxHealth Announces Results of Annual and Extraordinary General Shareholders' Meetings

Thursday, May 28, 2020 - 9:04pm

Press releaseRegulated information 28 May 2020, 11:00 p.m. CEST

Key Points: 
  • Press releaseRegulated information 28 May 2020, 11:00 p.m. CEST
    IRVINE, CA, and HERSTAL, BELGIUM 28 May 2020 MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, today held its annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM").
  • There was no attendance quorum for the AGM, and the proposed resolutions that were submitted to meeting were all duly passed.
  • The minutes of the AGM and documents that were submitted to the meetings can be accessed via the Companys website.
  • MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

Galapagos increases share capital through subscription right exercises

Thursday, May 28, 2020 - 9:01pm

Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Key Points: 
  • Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
  • Galapagos issued 435,540 new ordinary shares on 28 May 2020, for a total capital increase (including issuance premium) of 17,914,162.40.
  • CEO Onno van de Stolpe exercised 40,000 subscription rights.
  • This excludes the 2,280,500 subscription rights of Subscription Right Plan 2020 and Subscription Right Plan 2020 RMV, which were created subject to acceptance.

World’s Most Secure Cryptocurrency Hardware Wallet Beats Pre-Order Goal In 15 minutes

Thursday, May 28, 2020 - 5:00pm

NGRAVEs Indiegogo campaign successfully raised the quadruple of its funding goal in its first 24 hours.

Key Points: 
  • NGRAVEs Indiegogo campaign successfully raised the quadruple of its funding goal in its first 24 hours.
  • The next stretch goal will be unlocked at 150,000EUR, and will feature limited edition colors, available only to Indiegogo backers.
  • The NGRAVE product suite consists of hardware wallet NGRAVE ZERO, backup solution NGRAVE GRAPHENE, and mobile application NGRAVE LIQUID.
  • Developed with world leaders in nanoelectronics, hardware security and applied cryptography, NGRAVE ZEROs advanced features make it the most secure and easy to use crypto hardware wallet in the world.

Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders

Thursday, May 28, 2020 - 5:00pm

Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure.

Key Points: 
  • Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure.
  • Building on its proven alfapump platform, Sequana Medical is developing alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Biotalys awarded €1.6 million VLAIO research grant

Tuesday, May 26, 2020 - 7:00am

GHENT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it has been rewarded a 1.6 million research grant from Flanders Innovation & Entrepreneurship (VLAIO).

Key Points: 
  • GHENT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it has been rewarded a 1.6 million research grant from Flanders Innovation & Entrepreneurship (VLAIO).
  • The grant will run over three years and will support the accelerated development of cost-efficient microbial cell factories for the industrial production of Biotalys unique new generation protein-based biocontrol solutions.
  • There is a growing demand for safe, effective and price-compatible biocontrols, and establishing such a high-performance production platform uniquely positions Biotalys to address this need.
  • For further information, please contact Marieke Vermeersch Biotalys Corporate Communications Consultant T: +32 (0)479 490 603 E: marieke.vermeersch@biotalys.com Erica Camilo Connexa Communications for Biotalys T: +1 (610) 639 5644 E: erica@connexacommunications.com

Celyad Announces June 2020 Conference Schedule

Tuesday, May 26, 2020 - 6:00am

In particular it should be noted that the data summarized above are preliminary in nature.

Key Points: 
  • In particular it should be noted that the data summarized above are preliminary in nature.
  • There is limited data concerning safety and clinical activity following treatment with the CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series product candidates.
  • These results may not be repeated or observed in ongoing or future studies involving the CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series drug product candidates.
  • Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Hyloris appoints Patrick Jeanmart as Chief Financial Officer

Tuesday, May 26, 2020 - 6:00am

Lige, Belgium 26 May 2020: Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, announces the appointment of Patrick Jeanmart1 as Chief Financial Officer, with effect from 23 April 2020.

Key Points: 
  • Lige, Belgium 26 May 2020: Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, announces the appointment of Patrick Jeanmart1 as Chief Financial Officer, with effect from 23 April 2020.
  • Between 2007 and 2018, he served as Chief Financial Officer of Celyad, where he participated successfully in its development, first as a private and then as a public company (Euronext Brussels, Paris and NASDAQ).
  • Stijn Van Rompay, Chief Executive Officer and co-founder of Hyloris, commented: As an accomplished CFO, we are delighted to welcome Patrick to Hyloris.
  • Commenting on his appointment, Patrick Jeanmart added: I am pleased to be joining the highly capable team of Hyloris at this exciting time for the business.

MDxHealth Shareholder Transparency Declarations

Monday, May 25, 2020 - 7:00pm

Valiance Asset Management Limited notified MDxHealth that the aggregate number of shares with respect to which Valiance Asset Management Limited can exercise voting rights passively crossed below the threshold of 15% of the outstanding shares and voting rights of MDxHealth.

Key Points: 
  • Valiance Asset Management Limited notified MDxHealth that the aggregate number of shares with respect to which Valiance Asset Management Limited can exercise voting rights passively crossed below the threshold of 15% of the outstanding shares and voting rights of MDxHealth.
  • MVM Partners LLP notified MDxHealth that the aggregate number of shares with respect to which MVM Partners LLP can exercise voting rights actively crossed above the threshold of 20% of the outstanding shares and voting rights of MDxHealth.
  • 5) (which acquired 407,332 voting securities by way of subscription to a capital increase by MDxHealth).
  • MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.